United States

Genomic Health Inc (GHDX.O)

GHDX.O on Nasdaq

23 Jan 2017
Change (% chg)

-- (--)
Prev Close
Day's High
Day's Low
Avg. Vol
52-wk High
52-wk Low


Chart for GHDX.O


Genomic Health, Inc. is a healthcare company, which provides genomic-based diagnostic tests for the treatment of early stage cancer. The Company offers its Oncotype DX tests as a clinical laboratory service, where it analyzes the expression levels of genes in tumor tissue samples and provides physicians with a quantitative gene... (more)


Beta: 0.46
Market Cap(Mil.): $913.31
Shares Outstanding(Mil.): 33.48
Dividend: --
Yield (%): --


  GHDX.O Industry Sector
P/E (TTM): -- 44.03 29.85
EPS (TTM): -0.55 -- --
ROI: -12.73 -1.39 14.85
ROE: -13.00 -1.05 16.28

BRIEF-Genomic Health Q3 loss per share $0.08

* Genomic Health reports third consecutive quarter of double-digit revenue growth in announcement of third quarter 2016 financial results

Nov 01 2016

BRIEF-Genomic Health reports positive topline clinical validation study results

* Genomic Health announces positive topline clinical validation study results demonstrating Oncotype DX prostate cancer test predicts risk of metastasis and mortality Source text for Eikon: Further company coverage:

Nov 01 2016

BRIEF-Genomic Health files for mixed shelf of up to $350 mln - SEC filing

* Files for mixed shelf of up to $350 million - SEC filing Source: (http://bit.ly/2b0l97v ) Further company coverage:

Aug 11 2016

BRIEF-Genomic Health posts Q2 loss per share $0.18

* Is raising low end of both revenue and test guidance for full-year ending December 31, 2016

Aug 02 2016

Earnings vs. Estimates